Welcome to our dedicated page for Bitwise MARA Option Income Strategy ETF news (Ticker: IMRA), a resource for investors and traders seeking the latest updates and insights on Bitwise MARA Option Income Strategy ETF stock.
Bitwise MARA Option Income Strategy ETF (IMRA) reports fund updates tied to monthly distributions for Bitwise's Option Income Strategy ETF suite. News for the fund centers on distribution per share, distribution rate, 30-day SEC yield, payment dates, return of capital treatment, expenses, and performance periods.
Fund updates also describe risks associated with the option-income approach, including derivative instruments, leverage, issuer-specific volatility, and differences between derivatives and direct holdings of traditional securities.
Imara Inc. (Nasdaq: IMRA) reported promising results from its Phase 2a clinical trial of IMR-687 for treating sickle cell disease (SCD). Patients treated with IMR-687 experienced a 25% reduction in vaso-occlusive crises compared to placebo. Biomarker data showed significant improvements in markers of hemolysis and inflammation. IMR-687 was well tolerated, with no serious adverse effects noted. Future updates from the ongoing studies, including the Phase 2a open label extension and Phase 2b trials, are expected in 2021, indicating a strong focus on advancing the treatment.
Imara Inc. (Nasdaq: IMRA) presented preliminary data from its ongoing Phase 2a open label extension trial for IMR-687, an investigational treatment for sickle cell disease (SCD). Case reports showed increased HbF percentage and F-cell counts after six months of treatment. Improvements in clinical outcomes and biomarkers were also noted. IMR-687 was well tolerated when used alone or with hydroxyurea. Two patients reported significant reductions in vaso-occlusive crises (VOCs), with one experiencing a 55% decrease. The company plans to report further data in Q1 2021.
Imara Inc. (Nasdaq: IMRA) announced the presentation of clinical data from its ongoing IMR-687 Phase 2a clinical trial at the virtual American Society of Hematology Annual Meeting on December 5-8, 2020. The presentation, focusing on the benefits and safety of long-term use of IMR-687 in adult sickle cell patients, is scheduled for on-demand viewing on December 6. Imara completed dosing in the Phase 2a clinical trial in Q3 2020 and plans to report top-line data by late Q4 2020, with additional data expected in Q1 2021.
Imara Inc. (Nasdaq: IMRA) has appointed Lynette Hopkinson as Senior Vice President of Regulatory Affairs, bringing 25 years of pharmaceutical and biotech experience. Hopkinson's expertise in global regulatory strategy is expected to advance IMR-687's development for treating sickle cell disease and beta-thalassemia. She previously oversaw regulatory strategies at Vertex Pharmaceuticals and played a significant role in clinical development. IMR-687 aims to reactivate fetal hemoglobin in patients, potentially lowering disease burden.
Imara Inc. has initiated patient dosing in its Phase 2b clinical trials for IMR-687 targeting sickle cell disease and beta-thalassemia. The European Commission granted Orphan Drug designation for IMR-687 in treating sickle cell disease. The company's third-quarter results showed a net loss of $12.4 million, or $0.72 per share, an increase from $6.6 million in Q3 2019. R&D expenses rose to $9.5 million, driven by clinical trial costs. Imara expects R&D costs to be between $32 million and $37 million for 2020, projecting sufficient cash to fund operations into mid-2022.
Imara Inc. (Nasdaq: IMRA) will host a conference call and live webcast on November 5, 2020, at 8:30 a.m. ET to discuss its Q3 2020 financial results and business highlights. The company focuses on developing treatments for rare inherited genetic disorders of hemoglobin, including its lead product, IMR-687, a potential disease-modifying treatment for sickle cell disease and beta-thalassemia. Investors can access the webcast on the Imara website, and a replay will be available afterward.
Imara Inc. has commenced the Forte Phase 2b clinical trial of IMR-687 in patients with beta-thalassemia, marking a significant advancement in treatment options. This trial follows the initiation of the Ardent Phase 2b trial for sickle cell disease. The Forte trial aims to enroll about 120 adult patients, assessing the safety and effectiveness of IMR-687 in enhancing red blood cell maturation and reducing transfusion dependency. Beta-thalassemia affects approximately 288,000 individuals globally, underscoring the need for effective therapies.
BOSTON, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA) announced its participation in key virtual investor conferences this September. CEO Rahul Ballal, Ph.D., will present at the Citi 15th Annual BioPharma Virtual Conference on September 9 and 10, discussing challenges in rare disease drug development and benign hematology. Additionally, he will engage in a virtual fireside chat at the Morgan Stanley 18th Annual Global Healthcare Conference on September 17. Live webcasts will be available on Imara's website.
Imara Inc. (Nasdaq: IMRA) has received Orphan Drug designation from the European Commission for IMR-687, aimed at treating sickle cell disease (SCD). This designation highlights the critical need for effective SCD treatments, as the condition significantly impacts patients' lives. The company is advancing IMR-687 through a Phase 2b clinical trial. Orphan Drug designation provides several advantages, including market exclusivity, reduced fees, and specialized regulatory support, facilitating the development and approval process for this therapy.
Imara Inc. (Nasdaq: IMRA) has commenced Phase 2b clinical trials of IMR-687 for sickle cell disease and beta-thalassemia, with the first patient dosed in its Ardent trial. The company presented positive interim results at the European Hematology Association Congress, indicating improved outcomes with IMR-687 treatment. FDA granted multiple designations for IMR-687, enhancing its market prospects. Financially, Imara reported a net loss of $10.2 million for Q2 2020, an increase from $5.4 million year-over-year, yet its cash position stands at $106.3 million, sufficient to support operations into mid-2022.